Squarepoint’s SpringWorks Therapeutics SWTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-204,271
| Closed | -$9.6M | – | 4982 |
|
|
2025
Q2 | $9.6M | Buy |
+204,271
| New | +$9.09M | 0.01% | 1090 |
|
|
2025
Q1 | – | Sell |
-11,864
| Closed | -$546K | – | 5387 |
|
|
2024
Q4 | $429K | Sell |
11,864
-17,245
| -59% | -$603K | ﹤0.01% | 3866 |
|
|
2024
Q3 | $933K | Buy |
+29,109
| New | +$1.09M | ﹤0.01% | 2655 |
|
|
2024
Q2 | – | Sell |
-15,034
| Closed | -$740K | – | 4632 |
|
|
2024
Q1 | $740K | Buy |
+15,034
| New | +$695K | ﹤0.01% | 2796 |
|
|
2023
Q4 | – | Sell |
-33,768
| Closed | -$781K | – | 4489 |
|
|
2023
Q3 | $781K | Buy |
+33,768
| New | +$923K | ﹤0.01% | 2493 |
|
|
2022
Q4 | – | Sell |
-18,560
| Closed | -$530K | – | 3583 |
|
|
2022
Q3 | $530K | Sell |
18,560
-9,508
| -34% | -$273K | ﹤0.01% | 2180 |
|
|
2022
Q2 | $691K | Buy |
+28,068
| New | +$1.03M | ﹤0.01% | 1830 |
|
|
2022
Q1 | – | Sell |
-10,635
| Closed | -$659K | – | 3493 |
|
|
2021
Q4 | $659K | Sell |
10,635
-16,374
| -61% | -$1.08M | ﹤0.01% | 1971 |
|
|
2021
Q3 | $1.71M | Buy |
27,009
+11,256
| +71% | +$867K | ﹤0.01% | 1282 |
|
|
2021
Q2 | $1.3M | Buy |
15,753
+2,899
| +23% | +$220K | ﹤0.01% | 1447 |
|
|
2021
Q1 | $946K | Sell |
12,854
-4,781
| -27% | -$374K | 0.01% | 1549 |
|
|
2020
Q4 | $1.28M | Buy |
17,635
+9,992
| +131% | +$643K | 0.01% | 1175 |
|
|
2020
Q3 | $364K | Sell |
7,643
-8,411
| -52% | -$358K | ﹤0.01% | 1658 |
|
|
2020
Q2 | $674K | Buy |
+16,054
| New | +$571K | 0.01% | 1144 |
|
Other funds holding SWTX
Squarepoint's SWTX Position: Q3 2025 in Review
Squarepoint sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 204,271 shares — an estimated $9.6M sold.
Squarepoint first reported a position in SWTX in Q2 2020 and held it in 14 quarters. The position peaked at $9.6M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.
- Squarepoint reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
- Squarepoint sold 204,271 SpringWorks Therapeutics shares in Q3 2025, an estimated $9.6M.
- Squarepoint first reported a position in SpringWorks Therapeutics in Q2 2020 and held it in 14 quarters.
- Squarepoint's SpringWorks Therapeutics position peaked at $9.6M in Q2 2025.
- 3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.
Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.